期刊文献+
共找到11,824篇文章
< 1 2 250 >
每页显示 20 50 100
Efficacy of 5-Fluorouracil and High-Concentration Cisplatin Suspended in Lipiodol by Short-Term Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis 被引量:6
1
作者 Yutaka Yata Masashi Namikawa +8 位作者 Tatsuya Ohyama Takashi Ohsaki Daisuke Kanda Takeshi Hatanaka Kei Shibuya Jun Kubota Hitoshi Takagi Terumi Takahara Teruo Yoshinaga 《Journal of Cancer Therapy》 2015年第13期1151-1161,共11页
Background: Since advanced hepatocellular carcinoma (HCC) is potentially fatal, and patients’ quality of life (QOL) often deteriorates during their treatment, improving the prognosis and QOL of patients given chemoth... Background: Since advanced hepatocellular carcinoma (HCC) is potentially fatal, and patients’ quality of life (QOL) often deteriorates during their treatment, improving the prognosis and QOL of patients given chemotherapy is very important. In addition, cost-effective treatments are highly desirable when chemotherapy must be given repeatedly. The aim of this study was to evaluate the efficacy and usefulness of 5-fluorouracil (5-FU) and high-concentration cisplatin by short-term hepatic arterial infusion chemotherapy (3-day FPL) in advanced HCC patients. Methods: Thirty patients with unresectable advanced HCC were enrolled. The patients underwent hepatic arterial infusion chemotherapy via the implanted port system with 5-FU on days 1 - 3 and a fine-powder formulation of cisplatin in suspended pre-warmed lipiodol on day 2 every 4 to 10 weeks. Tumor response was assessed one month later with CT. Results: All patients had evidence of portal vein invasion (Vp2-4). Four patients achieved a complete response (CR), 8 patients achieved a partial response (PR), and 7 patients had stable disease (SD). The median progression-free survival (PFS) and overall survival (OS) were 198 days and 452 days, respectively. The OS was significantly longer in the successful disease control group (CR, PR, and SD) than in the progressive disease group (P < 0.005). Conclusions: Three-day FPL was effective and tolerable in advanced HCC patients due to its shorter time of administration than conventional FP therapy. Therefore, repetitive 3-day FPL appears useful and contributes to improving the prognosis and QOL of patients with advanced HCC. In addition, this protocol is a cost-effective treatment. 展开更多
关键词 Advanced Hepatocellular Carcinoma (HCC) Portal Vein Tumor THROMBOSIS (PVTT) Hepatic Arterial infusion Chemotherapy (HAIC) 5-FU a Fine-Powder Formulation of CISPLATIN Quality of Life (QOL) Cost-Effective Treatment
下载PDF
Predicting the prognosis of hepatic arterial infusion chemotherapy in hepatocellular carcinoma
2
作者 Qi-Feng Wang Zong-Wei Li +4 位作者 Hai-Feng Zhou Kun-Zhong Zhu Ya-Jing Wang Ya-Qin Wang Yue-Wei Zhang 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第6期2380-2393,共14页
Hepatic artery infusion chemotherapy(HAIC)has good clinical efficacy in the treatment of advanced hepatocellular carcinoma(HCC);however,its efficacy varies.This review summarized the ability of various markers to pred... Hepatic artery infusion chemotherapy(HAIC)has good clinical efficacy in the treatment of advanced hepatocellular carcinoma(HCC);however,its efficacy varies.This review summarized the ability of various markers to predict the efficacy of HAIC and provided a reference for clinical applications.As of October 25,2023,51 articles have been retrieved based on keyword predictions and HAIC.Sixteen eligible articles were selected for inclusion in this study.Comprehensive literature analysis found that methods used to predict the efficacy of HAIC include serological testing,gene testing,and imaging testing.The above indicators and their combined forms showed excellent predictive effects in retrospective studies.This review summarized the strategies currently used to predict the efficacy of HAIC in middle and advanced HCC,analyzed each marker's ability to predict HAIC efficacy,and provided a reference for the clinical application of the prediction system. 展开更多
关键词 Hepatocellular carcinoma Hepatic artery infusion chemotherapy PREDICTION PROGNOSIS IMAGING Biomarkers GENOMICS
下载PDF
Treatment of malignant digestive tract obstruction by combined intraluminal stent installation and intra-arterial drug infusion 被引量:6
3
作者 Ai-Wu Mao Zhong-Du Gao Jia-Yu Xu Ren-Jie Yang Xiang-Seng Xiao Ting-Hui Jiang Wei-Jun Jiang Department of Interventional Radiology,Shanghai S.T,Luke’s Hospital,768 Yu Yuan Road,Shanghai 200050,ChinaDepartment of Gastroenterology Rui Jin Hospital,Shanghai Second Medical University,Departrnent of Tumor Hospital,Beijing Medical UniversityDepartment of Imaging Chang Zheng Hospital,Shanghai Second Military Medical University 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第4期587-592,共6页
AIM: To study the palliative treatment of malignant obstruction of digestive tract with placement of intraluminal stent combined with intra-arterial infusion of chemotherapeutic drugs. METHODS: A total of 281 cases of... AIM: To study the palliative treatment of malignant obstruction of digestive tract with placement of intraluminal stent combined with intra-arterial infusion of chemotherapeutic drugs. METHODS: A total of 281 cases of digestive tract malignant obstruction were given per oral (esophagus, stomach, duodenum and jejunum), per anal (colon and rectum) and percutaneous transhepatic (biliary) installation of metallic stent. Among them, 203 cases received drug infusion by cannulation of tumor supplying artery with Seldinger's technique. RESULTS: Altogether 350 stents were installed in 281 cases, obstructive symptoms were relieved or ameliorated after installation. Occurrence of restenotic obstruction was 8-43 weeks among those with intra-arterial drug infusion, which was later than 4-26 weeks in the group with only stent installation. The average survival time of the former group was 43 (3-105) weeks, which was significantly longer than 13 (3-24) weeks of the latter group. CONCLUSION: Intraluminal placement of stent combined with intra-arterial infusion chemotherapy is one of the effective palliative therapies for malignant obstruction of the digestive tract with symptomatic as well as etiological treatment. 展开更多
关键词 STENTS Adult Aged Aged 80 and over Antineoplastic Agents DOSAGE Combined Modality Therapy Female Gastrointestinal Neoplasms Humans infusions Intra-Arterial Intestinal Obstruction Male Middle Aged Palliative Care Quality of Life Treatment Outcome
下载PDF
Quasi-Static, Poiseuille Flow of Analgesics from an Elastomeric Pump: Theoretical Determination of Infusion Times and Toxicity Conditions
4
作者 Clare B. Lipscombe Trevor C. Lipscombe Don S. Lemons 《Journal of Biosciences and Medicines》 2024年第9期251-265,共15页
Background: Elastomeric pumps (elastic balls into which analgesics or antibiotics can be inserted) push medicines through a catheter to a nerve or blood vessel. Since elastomeric pumps are small and need no power sour... Background: Elastomeric pumps (elastic balls into which analgesics or antibiotics can be inserted) push medicines through a catheter to a nerve or blood vessel. Since elastomeric pumps are small and need no power source, they fit easily into a pocket during infusion, allowing patient mobility. Elastomeric pumps are widely used and widely studied experimentally, but they have well-known problems, such as maintaining reliable flow rates and avoiding toxicity or other peak-and-trough effects. Objectives: Our research objective is to develop a realistic theoretical model of an elastomeric pump, analyze its flow rates, determine its toxicity conditions, and otherwise improve its operation. We believe this is the first such theoretical model of an elastomeric pump consisting of an elastic, medicine-filled ball attached to a horizontal catheter. Method: Our method is to model the system as a quasi-Poiseuille flow driven by the pressure drop generated by the elastic sphere. We construct an engineering model of the pressure exerted by an elastic sphere and match it to a solution of the one-dimensional radial Navier-Stokes equation that describes flow through a horizontal, cylindrical tube. Results: Our results are that the model accurately reproduces flow rates obtained in clinical studies. We also discover that the flow rate has an unavoidable maximum, which we call the “toxicity bump”, when the radius of the sphere approaches its terminal, unstretched value—an effect that has been observed experimentally. Conclusions: We conclude that by choosing the properties of an elastomeric pump, the toxicity bump can be restricted to less than 10% of the earlier, relatively constant flow rate. Our model also produces a relation between the length of time that the analgesic fluid infuses and the physical properties of the fluid, of the elastomeric sphere and the tube, and of the blood vessel into which the analgesic infuses. From these, we conclude that elastomeric pumps can be designed, using our simple model, to control infusion times while avoiding toxicity effects. 展开更多
关键词 Elastomeric Pump infusion Therapy Bio-Fluids Medical Devices Antibiotic Delivery Analgesic Delivery
下载PDF
Value of improved nursing measures and enhanced nursing management to reduce the occurrence of adverse events in pediatric infusion
5
作者 Yan-Song Lv Jv Xue +2 位作者 Zhu Meng Qing Zhang Xiao-Hong Liu 《World Journal of Clinical Cases》 SCIE 2024年第20期4130-4136,共7页
BACKGROUND Intravenous infusion is a common method of drug administration in clinical practice.Errors in any aspect of the infusion process,from the verification of medical orders,preparation of the drug solution,to i... BACKGROUND Intravenous infusion is a common method of drug administration in clinical practice.Errors in any aspect of the infusion process,from the verification of medical orders,preparation of the drug solution,to infusion by nursing staff,may cause adverse infusion events.AIM To analyzed the value of improving nursing measures and enhancing nursing management to reduce the occurrence of adverse events in pediatric infusion.METHODS The clinical data of 130 children who received an infusion in the pediatric department of our hospital from May 2020 to May 2021 were analyzed and divided into two groups according to the differences in nursing measures and nursing management:65 patients in the control group received conventional nursing and nursing management interventions,while 65 patients in the observation group received improved nursing measure interventions and enhanced nursing management.The occurrence of adverse events,compliance of children,satisfaction of children’s families,and complaints regarding the transfusion treatment were recorded in both groups.RESULTS The incidence of fluid extravasation and infusion set dislodgement in the observation group were 3.08%and 1.54%,respectively,which were significantly lower than 12.31%and 13.85%in the control group(P<0.05),while repeated punctures and medication addition errors in the observation group were 3.08%and 0.00%,respectively,which were lower than 9.23%and 3.08%in the control group,but there was no significant difference(P>0.05).The compliance rate of children in the observation group was 98.46%(64/65),which was significantly higher than 87.69%(57/65)in the control group,and the satisfaction rate of children’s families was 96.92%(63/65),which was significantly higher than 86.15%(56/65)in the control group(P<0.05).The observation group did not receive any complaints from the child’s family,whereas the control group received four complaints,two of which were due to the crying of the child caused by repeated punctures,one due to the poor attitude of the nurse,and one due to medication addition errors,with a cumulative complaint rate of 6.15%.The cumulative complaint rate of the observation group was significantly lower than that of the control group(P<0.05).CONCLUSION Improving nursing measures and enhancing nursing management can reduce the incidence of fluid extravasation and infusion set dislodgement in pediatric patients,improve children’s compliance and satisfaction of their families,and reduce family complaints. 展开更多
关键词 Improved nursing measures Improved nursing management Pediatric infusion Adverse events COMPLIANCE Family complaints
下载PDF
Propofol sedation in routine endoscopy:A case series comparing target controlled infusion vs manually controlled bolus concept
6
作者 Riad Sarraj Lorenz Theiler +2 位作者 Nima Vakilzadeh Niklas Krupka Reiner Wiest 《World Journal of Gastrointestinal Endoscopy》 2024年第1期11-17,共7页
BACKGROUND Many studies have addressed safety and effectiveness of non-anaesthesiologist propofol sedation(NAPS)for gastrointestinal(GI)endoscopy Target controlled infusion(TCI)is claimed to provide an optimal sedatio... BACKGROUND Many studies have addressed safety and effectiveness of non-anaesthesiologist propofol sedation(NAPS)for gastrointestinal(GI)endoscopy Target controlled infusion(TCI)is claimed to provide an optimal sedation regimen by avoiding under-or oversedation.AIM To assess safety and performance of propofol TCI sedation in comparison with nurse-administered bolus-sedation.METHODS Fouty-five patients undergoing endoscopy under TCI propofol sedation were prospectively included from November 2016 to May 2017 and compared to 87 patients retrospectively included that underwent endoscopy with NAPS.Patients were matched for age and endoscopic procedure.We recorded time of sedation and endoscopy,dosage of medication and adverse events.RESULTS There was a significant reduction in dose per time of propofol administered in the TCI group,compared to the NAPS group(8.2±2.7 mg/min vs 9.3±3.4 mg/min;P=0.046).The time needed to provide adequate sedation levels was slightly but significantly lower in the control group(5.3±2.7 min vs 7.7±3.3 min;P<0.001),nonetheless the total endoscopy time was similar in both groups.No differences between TCI and bolus-sedation was observed for mean total-dosage of propofol rate as well as adverse events.CONCLUSION This study indicates that sedation using TCI for GI endoscopy reduces the dose of propofol necessary per minute of endoscopy.This may translate into less adverse events.However,further and randomized trials need to confirm this trend. 展开更多
关键词 SEDATION ENDOSCOPY PROPOFOL Target controlled infusion Non-anaesthesiologist propofol sedation Adverse event
下载PDF
Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation 被引量:8
7
作者 Yifei Cheng Yuhong Chen +11 位作者 Chenhua Yan Yu Wang Xiangyu Zhao Yao Chen Wei Han Lanping Xu Xiaohui Zhang Kaiyan Liu Shasha Wang Lungji Chang Lei Xiao Xiaojun Huang 《Engineering》 SCIE EI 2019年第1期150-155,共6页
Leukemia relapse is still the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for B cell acute lymphoblastic leukemia (B-ALL). Relapsed patients with BALL after ... Leukemia relapse is still the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for B cell acute lymphoblastic leukemia (B-ALL). Relapsed patients with BALL after allo-HSCT have a very short median survival. Minimal residual disease (MRD) is predictive of forthcoming hematological relapse after hematopoietic stem cell transplantation (HSCT);furthermore, eliminating MRD effectively prevents relapse. Donor lymphoblastic infusion (DLI) is the main established approach to treat B-ALL with MRD after allo-HSCT. However, about one-third of patients with MRD are non-responsive to DLI and their prognosis worsens. Although donor-derived cluster of differentiation (CD)19-directed chimeric antigen receptor-modified (CAR) T cells (CART19s) can potentially cure leukemia, the efficiency and safety of infusions with these cells have not yet been investigated in patients with MRD after HSCT. Between September 2014 and February 2018, six patients each received one or more infusions of CART19s from HSCT donors. Five (83.33%) achieved MRD-negative remission, and one case was not responsive to the administration of CAR T cells. Three of the six patients are currently alive without leukemia. No patient developed acute graft-versus-host disease (aGVHD), and no patient died of cytokine release syndrome. Donor-derived CAR T cell infusions seem to be an effective and safe intervention for patients with MRD in B-ALL after allo-HSCT and for those who were not responsive to DLI. 展开更多
关键词 Donor-derived CD19-targeted T CELL infusion Hematopoietic stem CELL transplantation B CELL acute lymphoblastic leukemia Minimal residual disease
下载PDF
氯喹对胰岛素抵抗大鼠胰岛素降解酶基因及酶蛋白表达的影响 被引量:2
8
作者 李晨钟 张素华 +1 位作者 薛耀明 任伟 《广东医学》 CAS CSCD 北大核心 2005年第11期1461-1462,共2页
目的了解氯喹对大鼠肝脏胰岛素降解酶(insulin-degrading enzyme,IDE)基因表达(expression of IDE gene,EIG)及酶蛋白表达(expression of IDE protein,EIP)水平的影响.方法以高脂肪饮食喂养法复制的胰岛素抵抗(insulin resistance,IR)Wi... 目的了解氯喹对大鼠肝脏胰岛素降解酶(insulin-degrading enzyme,IDE)基因表达(expression of IDE gene,EIG)及酶蛋白表达(expression of IDE protein,EIP)水平的影响.方法以高脂肪饮食喂养法复制的胰岛素抵抗(insulin resistance,IR)Wistar大鼠模型为对象,检测IR大鼠肝脏EIG,EIP水平和肝脏IDE活性,并测定大鼠的平均葡萄糖输注率(glucose infusion rate,GIR60-120),同时观察氯喹对上述指标的影响.结果IR大鼠的EIG,EIP水平显著高于常规饲料喂养的对照大鼠.服用氯喹后,IR大鼠EIG,EIP水平显著降低,对照大鼠的上述指标无明显改变.IR大鼠和对照大鼠的肝脏IDE活性均与EIG,EIP水平呈显著正相关,而与GIR60-120呈显著负相关.结论氯喹降低IR大鼠IDE活性可能是通过抑制IDE基因转录,从而降低IDE酶蛋白表达量来实现. 展开更多
关键词 infusion protein IDE P gene rate IR EI
下载PDF
Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis 被引量:4
9
作者 Yu-Zhe Cao Guang-Lei Zheng +4 位作者 Tian-Qi Zhang Hong-Yan Shao Jia-Yu Pan Zi-Lin Huang Meng-Xuan Zuo 《World Journal of Gastroenterology》 SCIE CAS 2024年第4期318-331,共14页
BACKGROUND Hepatic arterial infusion chemotherapy(HAIC)has been proven to be an ideal choice for treating unresectable hepatocellular carcinoma(uHCC).HAIC-based treatment showed great potential for treating uHCC.Howev... BACKGROUND Hepatic arterial infusion chemotherapy(HAIC)has been proven to be an ideal choice for treating unresectable hepatocellular carcinoma(uHCC).HAIC-based treatment showed great potential for treating uHCC.However,large-scale studies on HAIC-based treatments and meta-analyses of first-line treatments for uHCC are lacking.AIM To investigate better first-line treatment options for uHCC and to assess the safety and efficacy of HAIC combined with angiogenesis inhibitors,programmed cell death of protein 1(PD-1)and its ligand(PD-L1)blockers(triple therapy)under real-world conditions.METHODS Several electronic databases were searched to identify eligible randomized controlled trials for this meta-analysis.Study-level pooled analyses of hazard ratios(HRs)and odds ratios(ORs)were performed.This was a retrospective single-center study involving 442 patients with uHCC who received triple therapy or angiogenesis inhibitors plus PD-1/PD-L1 blockades(AIPB)at Sun Yat-sen University Cancer Center from January 2018 to April 2023.Propensity score matching(PSM)was performed to balance the bias between the groups.The Kaplan-Meier method and cox regression were used to analyse the survival data,and the log-rank test was used to compare the suvival time between the groups.RESULTS A total of 13 randomized controlled trials were included.HAIC alone and in combination with sorafenib were found to be effective treatments(P values for ORs:HAIC,0.95;for HRs:HAIC+sorafenib,0.04).After PSM,176 HCC patients were included in the analysis.The triple therapy group(n=88)had a longer median overall survival than the AIPB group(n=88)(31.6 months vs 14.6 months,P<0.001)and a greater incidence of adverse events(94.3%vs 75.4%,P<0.001).CONCLUSION This meta-analysis suggests that HAIC-based treatments are likely to be the best choice for uHCC.Our findings confirm that triple therapy is more effective for uHCC patients than AIPB. 展开更多
关键词 Unresectable hepatocellular carcinoma Hepatic arterial infusion chemotherapy Angiogenesis inhibitors Programmed cell death protein 1 Programmed death ligand 1
下载PDF
Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma:A network meta-analysis 被引量:2
10
作者 Shun-An Zhou Qing-Mei Zhou +7 位作者 Lei Wu Zhi-Hong Chen Fan Wu Zhen-Rong Chen Lian-Qun Xu Bi-LingGan Hao-Sheng Jin Ning Shi 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第8期3672-3686,共15页
BACKGROUND With the rapid progress of systematic therapy for hepatocellular carcinoma(HCC),therapeutic strategies combining hepatic arterial infusion chemotherapy(HAIC)with systematic therapy arised increasing concent... BACKGROUND With the rapid progress of systematic therapy for hepatocellular carcinoma(HCC),therapeutic strategies combining hepatic arterial infusion chemotherapy(HAIC)with systematic therapy arised increasing concentrations.However,there have been no systematic review comparing HAIC and its combination strategies in the first-line treatment for advanced HCC.AIM To investigate the efficacy and safety of HAIC and its combination therapies for advanced HCC.METHODS A network meta-analysis was performed by including 9 randomized controlled trails and 35 cohort studies to carry out our study.The outcomes of interest comprised overall survival(OS),progression-free survival(PFS),tumor response and adverse events.Hazard ratios(HR)and odds ratios(OR)with a 95% confidence interval(CI)were calculated and agents were ranked based on their ranking probability.RESULTS HAIC outperformed Sorafenib(HR=0.55,95%CI:0.42-0.72;HR=0.51,95%CI:0.33-0.78;OR=2.86,95%CI:1.37-5.98;OR=5.45,95%CI:3.57-8.30;OR=7.15,95%CI:4.06-12.58;OR=2.89,95%CI:1.99-4.19;OR=0.48,95%CI:0.25-0.92,respectively)and transarterial chemoembolization(TACE)(HR=0.50,95%CI:0.33-0.75;HR=0.62,95%CI:0.39-0.98;OR=3.08,95%CI:1.36-6.98;OR=2.07,95%CI:1.54-2.80;OR=3.16,95%CI:1.71-5.85;OR=2.67,95%CI:1.59-4.50;OR=0.16,95%CI:0.05-0.54,respectively)in terms of efficacy and safety.HAIC+lenvatinib+ablation,HAIC+ablation,HAIC+anti-programmed cell death 1(PD-1),and HAIC+radiotherapy had the higher likelihood of providing better OS and PFS outcomes compared to HAIC alone.HAIC+TACE+S-1,HAIC+lenvatinib,HAIC+PD-1,HAIC+TACE,and HAIC+sorafenib had the higher likelihood of providing better partial response and objective response rate outcomes compared to HAIC.HAIC+PD-1,HAIC+TACE+S-1 and HAIC+TACE had the higher likelihood of providing better complete response and disease control rate outcomes compared to HAIC alone.CONCLUSION HAIC proved more effective and safer than sorafenib and TACE.Furthermore,combined with other interventions,HAIC showed improved efficacy over HAIC monotherapy according to the treatment ranking analysis. 展开更多
关键词 Hepatic arterial infusion chemotherapy Hepatocellular carcinoma Network meta-analysis Interventional therapy Systemic treatment
下载PDF
Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus 被引量:6
11
作者 Lin-Zhong Zhu Song Xu Hai-Long Qian 《World Journal of Gastroenterology》 SCIE CAS 2018年第23期2501-2507,共7页
AIM To determine the efficacy and safety of transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed in hepatocellular carcinoma(HCC) with major portal... AIM To determine the efficacy and safety of transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed in hepatocellular carcinoma(HCC) with major portal vein tumor thrombus(MPVTT).METHODS eighty-six patients with MPVTT accepted routine embolization. The catheter was kept in the hepatic artery and oxaliplatin(50 mg in 250 m L of glucose) was infused by pump for 4 h,followed by raltitrexed(2 mg in 100 m L of 0.9% saline) infusion by pump for the next 1 h. The efficacy and safety were evaluated afterthe transarterial chemoembolization(TACe).RESULTS Full or partial embolization was achieved in 86 cases,where all the cases received low dose continuous hepatic arterial infusion chemotherapy. Complete responses(CRs),partial responses(PRs),stable disease(SD),and disease progression(PD) for intrahepatic disease were observed in 0,45,20,and 21 patients,respectively. The 1-,2-and 3-year overall survival rates of the 86 patients were 40.7%,22.1%,and 8.1% respectively,and the median survival time was 8.7 mo. Complication was limited. CONCLUSION TACE with low dose continuous hepatic arterial infusion of oxaliplatin and raltitrexed could be an option in MPVTT patient; it was shown to be effective in patients with advanced HCC with MPVTT with less toxicity. 展开更多
关键词 Transarterial EMBOLIZATION OXALIPLATIN MAJOR portal vein tumor THROMBUS RALTITREXED CONTINUOUS hepatic arterial infusion chemotherapy
下载PDF
Anthocyanins from purple corn affect gut microbiota and metabolome in inflammatory bowel disease patients under infliximab infusion: the SiCURA pilot study
12
作者 Mirco Vacca Eduardo Maria Sommella +16 位作者 Marina Liso Giulio Verna Aurelia Scarano Annamaria Sila Margherita Curlo Mauro Mastronardi Katia Petroni Chiara Tonelli Bruno Di Jeso Angelo Santino Vincenzo Vestuto Fabrizio Merciai Gianluigi Giannelli Pietro Campiglia Maria De Angelis Marcello Chieppa Francesco Maria Calabrese 《Food Science and Human Wellness》 SCIE CAS CSCD 2024年第6期3536-3543,共8页
Nowadays,inflammatory bowel disease(IBD)-patient therapies are mainly based on corticosteroid,thiopurine,and immunomodulator treatments.Patients with active disease,that do not respond to corticosteroid and/or thiopur... Nowadays,inflammatory bowel disease(IBD)-patient therapies are mainly based on corticosteroid,thiopurine,and immunomodulator treatments.Patients with active disease,that do not respond to corticosteroid and/or thiopurine treatment,can switch to the usage of the chimeric monoclonal antibody infliximab(IFX).However,to date,no treatment appeared to be conclusive in lowering the incidence of IBD relapses.With the aim to increase the effectiveness of IFX treatment,we combined it with an adjuvant purple corn supplementation enriched in anthocyanins.IBD-patients were enrolled before they underwent to the IFX-infusion,and they were allocated in 2 different study arms.Patients in the intervention-arm followed a dietary supplementation with purple corn water-soluble extract,whereas control patients had a daily consumption of red fruit tea.16S rDNA gene-sequencing and high-resolution mass-spectrometry metabo-lipidomics analyses were conducted on stool and sera samples,respectively.As a result,the experimental intervention mainly affected the serum metabolome of IBD-patients by decreasing the concentration of specific lipids.Focusing on IBD patient annotated taxa,a significant decrease in Lactobacillus and Bifi dobacterium relative abundances was found.As far as it concerns the ulcerative colitis patient subset,the experimental intervention led to a decrease in Alistipes and Erysipelotrichaceae UCG-003 genus abundances and a concomitant Parabacteroides increase.On the contrary,after treatment,Crohn’s disease patients did not exhibit metataxonomics differences at the genus level.At the end of the treatment that led to a reshaped microbiota community,the gathered data paves the way for the usage of a specifically designed probiotic supplementation as a valuable strategy for IBD-patients under IFX infusion. 展开更多
关键词 Inflammatory bowel disease infliximab infusion ANTIOXIDANTS NUTRIGENOMICS Adjuvant therapy
下载PDF
Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma
13
作者 Zhi-Peng Lin Xiao-Long Hu +7 位作者 Du Chen Da-Bei Huang Xu-Gong Zou Hai Zhong Sheng-Xiang Xu Yuan Chen Xiao-Qun Li Jian Zhang 《World Journal of Gastroenterology》 SCIE CAS 2024年第17期2321-2331,共11页
BACKGROUND The advent of cutting-edge systemic therapies has driven advances in the treatment of hepatocellular carcinoma(HCC),and therapeutic strategies with multiple modes of delivery have been shown to be more effi... BACKGROUND The advent of cutting-edge systemic therapies has driven advances in the treatment of hepatocellular carcinoma(HCC),and therapeutic strategies with multiple modes of delivery have been shown to be more efficacious than mono-therapy.However,the mechanisms underlying this innovative treatment modality have not been elucidated.AIM To evaluate the clinical efficacy of targeted therapy plus immunotherapy combined with hepatic arterial infusion chemotherapy(HAIC)of FOLFOX in patients with unresectable HCC.METHODS We enrolled 53 patients with unresectable HCC who received a combination of targeted therapy,immunotherapy,and HAIC of FOLFOX between December 2020 and June 2021 and assessed the efficacy and safety of the treatment regimen.RESULTS The objective response rate was 60.4%(32/53),complete response was 24.5%(13/53),partial response was 35.9%(19/53),and stable disease was 39.6%(21/53).The median duration of response and median progression-free survival were 9.1 and 13.9 months,respectively.The surgical conversion rate was 34.0%(18/53),and 1-year overall survival was 83.0%without critical complicating diseases or adverse events(AEs).CONCLUSION The regimen of HAIC of FOLFOX,targeted therapy,and immunotherapy was curative for patients with unresectable HCC,with no serious AEs and a high rate of surgical conversion. 展开更多
关键词 Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Targeted therapy IMMUNOTHERAPY Adverse events
下载PDF
Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma
14
作者 Douglas Dias E Silva Mitesh Borad Pedro Luiz Serrano Uson Junior 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第12期4766-4769,共4页
Newer systemic therapies for hepatocellular carcinoma(HCC)have led to growing interest in combining hepatic arterial infusion chemotherapy(HAIC)with systemic treatments.To evaluate the effectiveness and safety of HAIC... Newer systemic therapies for hepatocellular carcinoma(HCC)have led to growing interest in combining hepatic arterial infusion chemotherapy(HAIC)with systemic treatments.To evaluate the effectiveness and safety of HAIC and combination therapies in treating advanced HCC,a network meta-analysis was conducted by Zhou et al.The study included data from 44 articles.HAIC was superior in overall survival(OS),progression-free survival(PFS),and response rates compared to transarterial chemoembolization and sorafenib.Moreover,combinations of HAIC with other treatments and single agents(e.g.,lenvatinib,ablation,anti-programmed cell death 1 therapy,radiotherapy)provided better OS and PFS outcomes than HAIC alone.In this editorial,we will discuss the study findings,the strengths and weaknesses of the metanalysis,and future advances in the field of HAIC for advanced HCC. 展开更多
关键词 Hepatic arterial infusion CHEMOTHERAPY Hepatocellular carcinoma Liver cancer SURVIVAL
下载PDF
护理干预对学龄前患儿接受静脉输液的影响 被引量:7
15
作者 郑文静 欧梅娇 许梅 《上海护理》 2005年第3期10-11,共2页
目的探讨学龄前患儿在接受静脉输液时的心理状况与影响因素,从而采取针对性的护理干预。方法选择在我院门诊输液室输液的学龄前患儿208例分成观察组109例和对照组99例,观察组运用沟通技巧实施心理疏导,对照组则予以常规护理。观察两组... 目的探讨学龄前患儿在接受静脉输液时的心理状况与影响因素,从而采取针对性的护理干预。方法选择在我院门诊输液室输液的学龄前患儿208例分成观察组109例和对照组99例,观察组运用沟通技巧实施心理疏导,对照组则予以常规护理。观察两组患儿静脉穿刺时的行为状况和静脉穿刺的成功率。结果观察组在配合治疗的主动性和静脉穿刺的成功率均明显高于对照组,经χ2检验差异有显著性(P<0.01)。结论有效的护理干预可提高学龄前患儿对静脉输液的依从性,从而提高静脉穿刺的成功率。 展开更多
关键词 穿 X^2 穿
下载PDF
Flow Rate Measurement of Gravity Infusion Set and Functional Evaluation of Drop Counter: A Pilot Study
16
作者 Rina Sakai Shuichi Tanaka +3 位作者 Kaya Murakami Tomomi Mizuhashi Kazuhiro Yoshida Masanobu Ujihira 《Journal of Biomedical Science and Engineering》 2024年第7期129-135,共7页
Developing a novel drop counter by introducing the Internet of Things concept has been vigorously conducted in recent years. Understanding the newly introduced drop counter’s flow rate control accuracy and flow rate ... Developing a novel drop counter by introducing the Internet of Things concept has been vigorously conducted in recent years. Understanding the newly introduced drop counter’s flow rate control accuracy and flow rate count feature is essential for improving safety in infusion management. This study aimed to verify if the new drop counters could secure accurate flow rate and drip count by conducting actual flow rate measurements using gravimetry and functional evaluation. A drop counter was attached to each drip chamber of the infusion set, and an IV drip was conducted at the 100 ml/h flow rate. The weight of discharged physiological saline was measured to plot trumpet curves. Next, three different types of drop counters were evaluated to determine if they maintained drip count accuracy according to the changes in their position angles. The flow rate errors in all conditions indicated trumpet-like curves, exhibiting an overall error range within ±10% in all observation windows. Although every drop counter successfully detected and measured dripping, it was challenging in some counters to detect dripping when the drip chamber was tilted. In comparing adult and pediatric IV sets, the adult IV set was found to be less likely to detect dripping in the angled position. No significant differences in results were confirmed between high and low flow rates, suggesting that the drop count function would not be affected by the flow rate in the ranges of typical infusion practices. Doppler sensors have a wide range of measurements and high sensitivity;the dripping was detected successfully even when the drip chamber was tilted, probably due to the advantages of these sensors. In contrast, miscounts occurred in those equipped with infrared sensors, which could not detect light intensity changes in tilted positions. Understanding the tendencies in flow rate errors in infusion can be valuable information for infusion management. 展开更多
关键词 Gravity infusion Set Drop Counter IV Fluids Flow Rate Trumpet Curves
下载PDF
Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma 被引量:7
17
作者 Yang Zhao Jia Ying Lai +2 位作者 Run Bin Liang Min Ke He Ming Shi 《Journal of Interventional Medicine》 2019年第2期78-83,共6页
Objective:To compare the efficacy of sorafenib plus hepatic arterial infusion chemotherapy(HAIC)with oxaliplatin to that of sorafenib alone in patients with advanced hepatocellular carcinoma(HCC).Methods:This was a re... Objective:To compare the efficacy of sorafenib plus hepatic arterial infusion chemotherapy(HAIC)with oxaliplatin to that of sorafenib alone in patients with advanced hepatocellular carcinoma(HCC).Methods:This was a retrospective,single-center trial.Between April 3,2017 and July 2,2018,104 patients with Child-Pugh A and advanced HCC received either 400 mg of sorafenib orally twice daily plus HAIC with oxaliplatin(oxaliplatin 85 mg/m^2,every 3 weeks via repetitive catheterization)(n=46,soraOXA group)or 400 mg of only sorafenib orally twice daily(n=58,sorafenib group).Overall survival,progression-free survival,objective response rate,and treatment-related adverse events were compared.Results:The median overall survival was 9.37 months(95%CI,7.05-11.68)in the soraOXA group versus 4.8 months(95%CI,2.98-6.62)in the sorafenib group(HR 0.46[95%CI,0.29-0.72];P<0.001).The soraOXA group also showed a higher objective response rate(16[34.8%]vs 1[1.7%];P<0.001)and a longer progressionfree survival rate(5.5 months[95%CI,2.32-8.68]vs 2.4 months[95%CI,1.65-3.15],HR 0.54[95%CI,0.36-0.81],P=0.003)than the sorafenib group.There was no significant difference in the overall incidence of any grade adverse events,grade 3/4 adverse events,serious adverse events,or incidence of treatment termination due to adverse events between the two groups.Conclusion:Compared with sorafenib alone,sorafenib plus HAIC with oxaliplatin showed favorable treatment outcomes in patients with advanced HCC.The merits of this approach need to be established with a prospective trial. 展开更多
关键词 Hepatocellular carcinoma BARCELONA CLINIC liver cancer stage C SORAFENIB Hepatic arterial infusion chemotherapy OXALIPLATIN
下载PDF
Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy
18
作者 Eda Caliskan Yildirim Yakup Ergun 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第12期4757-4761,共5页
Hepatocellular carcinoma(HCC)remains a major challenge in oncology,being a leading cause of cancer-related mortality worldwide.Early-stage HCC is typically treated with surgical resection,transplantation,or ablation,w... Hepatocellular carcinoma(HCC)remains a major challenge in oncology,being a leading cause of cancer-related mortality worldwide.Early-stage HCC is typically treated with surgical resection,transplantation,or ablation,while advanced-stage HCC relies on systemic therapies like sorafenib and newer combinations such as atezolizumab-bevacizumab.Despite these advancements,there is still a need for effective treatments for unresectable HCC,especially in cases with macroscopic vascular invasion.Hepatic arterial infusion chemotherapy(HAIC)has demonstrated promising outcomes in Asia for the treatment of unresectable HCC,yet its application in Western countries has been relatively limited.This letter reviews the recent meta-analysis by Zhou et al published in the World Journal of Gastrointestinal Oncology,which demonstrates the efficacy and safety of HAIC vs sorafenib.The analysis includes 9 randomized controlled trials and 35 cohort studies,highlighting significant improvements in overall survival,progressionfree survival,and objective response rates with HAIC and its combinations.The editorial explores the reasons behind the limited use of HAIC in Western countries.It underscores the potential of HAIC to enhance treatment outcomes for advanced HCC and calls for more research and broader adoption of HAIC in clinical practice globally. 展开更多
关键词 Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Tyrosine kinase inhibitors IMMUNOTHERAPY SURVIVAL
下载PDF
Application of Patient Simulators Combined with Internet plus Scenario Simulation Teaching Models on Intravenous Infusion Nursing Education in China
19
作者 Ying Wu Yun Chen +5 位作者 Liuyan Zhang Guohua Huang Jinai He Yutong Li Yuzhen Renqing Zhijuan Zhan 《Journal of Biosciences and Medicines》 2024年第1期64-71,共8页
Objective: To explore the effectiveness of applying patient simulators combined with Internet Plus scenario simulation teaching models on intravenous (IV) infusion nursing education, and to provide scientific evidence... Objective: To explore the effectiveness of applying patient simulators combined with Internet Plus scenario simulation teaching models on intravenous (IV) infusion nursing education, and to provide scientific evidence for the implementation of advanced teaching models in future nursing education. Methods: Enrolled 60 nurses who took the IV infusion therapy training program in our hospital from January 2022 to December 2023 for research. 30 nurses who were trained in traditional teaching models from January to December 2022 were selected as the control group, and 30 nurses who were trained with simulation-based teaching models with methods including simulated patients, internet, online meetings which can be replayed and scenario simulation, etc. from January to December 2023 were selected as the experimental group. Evaluated the learning outcomes based on the Competency Inventory for Nursing Students (CINS), Problem-Solving Inventory (PSI), comprehensive learning ability, scientific research ability, and proficiency in the theoretical knowledge and practical skills of IV infusion therapy. Nursing quality, the incidence of IV infusion therapy complications and nurse satisfaction with different teaching models were also measured. Results: The scientific research ability, PSI scores, CINS scores, and comprehensive learning ability of the experimental group were better than those of the control group (P 0.05), and their assessment results of practical skills, nursing quality of IV infusion therapy during training, and satisfaction with teaching models were all better than those of the control group with statistical significance (P < 0.05). The incidence of IV infusion therapy complications in the experimental group was lower than that in the control group, indicating statistical significance (P < 0.05). Conclusions: Teaching models based on patient simulators combined with Internet Plus scenario simulation enable nursing students to learn more directly and practice at any time and in any place, and can improve their proficiency in IV infusion theoretical knowledge and skills (e.g. PICC catheterization), core competencies, problem-solving ability, comprehensive learning ability, scientific research ability and the ability to deal with complicated cases. Also, it helps provide high-quality nursing education, improve the nursing quality of IV therapy, reduce the incidence of related complications, and ensure the safety of patients with IV therapy. 展开更多
关键词 Specialty of Intravenous infusion Therapy Nursing Education Patient Simulators Internet Plus Scenario Simulation Teaching Model
下载PDF
单纯丙泊酚及复合瑞芬太尼靶控输注用于无痛人工流产术的比较 被引量:3
20
作者 吕洁萍 刘保江 +1 位作者 韩冲芳 余淑珍 《山西医药杂志》 CAS 2005年第6期456-458,共3页
目的比较丙泊酚复合瑞芬太尼靶控输注与单纯丙泊酚靶控输注用于无痛人工流产(人流)术的效果,探讨合理的静脉麻醉方法。方法80例美国麻醉医师协会(ASA)Ⅰ级接受无痛人流术的病人,分为两组,单纯丙泊酚靶控输注(TCI)组(P组)和丙泊酚复合瑞... 目的比较丙泊酚复合瑞芬太尼靶控输注与单纯丙泊酚靶控输注用于无痛人工流产(人流)术的效果,探讨合理的静脉麻醉方法。方法80例美国麻醉医师协会(ASA)Ⅰ级接受无痛人流术的病人,分为两组,单纯丙泊酚靶控输注(TCI)组(P组)和丙泊酚复合瑞芬太尼TCI组(PR组),每组40例。P组:丙泊酚血浆靶浓度为6~7mg/L;PR组:丙泊酚血浆靶浓度为3.5~4mg/L、瑞芬太尼血浆靶浓度为1.8~2μg/L。待病人意识消失(睫毛反射消失、呼之不应)后开始手术,扩张宫颈结束时停止给药。结果①麻醉效果PR组优于P组(P<0.05)。②PR组诱导时间(1.1±0.4)min,明显短于P组(P<0.05),PR组丙泊酚总剂量(1.8±0.4)mg/kg,明显少于P组(P<0.01)。③苏醒期躁动、兴奋多语P组发生率分别为55%、50%,PR组未发生(P<0.01)。④两组麻醉后血压均明显下降(P<0.01),扩宫时最低,停药后很快回升,负压吸引时恢复至麻醉前水平(P>0.05),各时段脑电双频指数(BIS)值明显下降(P<0.01,P<0.05),负压吸引时最低,以后逐渐回升。结论在无痛人流术中,丙泊酚复合瑞芬太尼靶控输注优于单纯丙泊酚靶控输注,麻醉效果好、诱导时间短、显著减少丙泊酚用量、减少不良反应,是一种安全、合理的静脉麻醉方法。 展开更多
关键词 PR TCI
下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部